Date: 01/29/07 (Java Web)    Keywords: no keywords

A large study, conducted by Dr. James M. Brophy and his colleagues, from the McGill University Health Center in Montreal, confirms that selective COX2 inhibitors - Vioxx (rofecoxib) and Celebrex (celecoxib) are both associated with increased risk of repeat heart attack. They also found that Vioxx (rofecoxib), but not Celebrex (celecoxib), is associated with increased [...]

Source: http://blog.taragana.com/index.php/archive/vioxx-celebrex-raise-risk-of-first-repeat-heart-attack-large-study/